Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Viscosupplementation Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Viscosupplementation for Osteoarthritis Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for intra-articular viscosupplementation products used to treat knee osteoarthritis in commercial members. Coverage requires documented clinical criteria, failure of conservative therapies, appropriate treatment timing, absence of contraindications, and FDA-labeled dosing.

    Policy Summary
    PayerPrime Therapeutics
    PolicyViscosupplementation for Osteoarthritis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date03-15-2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming qualifying knee osteoarthritis, required treatment trials, appropriate treatment timing, absence of contraindications, and FDA-labeled dosing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 moApproval length
    3 moNon-pharmacologic trial
    3 moPharmacologic trial
    6 moCorticosteroid interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 moRepeat-course interval
    5+Clinical findings threshold

    Viscosupplementation Coverage Criteria

    Viscosupplementation approval criteria

    Covered when all of the following are met.

    All approval criteria

    • Diagnosis of knee osteoarthritis

      • Radiographic findings: At least one of the following: joint space narrowing; sub-chondral sclerosis; or osteophytes and sub-chondral cysts.at least 1
      • Clinical and laboratory findings: At least five of the following: bony enlargement; bony tenderness; crepitus on active motion; erythrocyte sedimentation rate less than 40 mm/hr; morning stiffness less than 30 minutes; no palpable warmth of synovium; rheumatoid factor less than 1:40 titer; or synovial fluid that is clear, of normal viscosity, and has a white blood cell count less than 2,000/mm3.at least 5
    • Symptoms and prior treatment: The patient has pain interfering with functional activities such as walking and prolonged standing; the pain is not attributed to another form of joint disease based on a differential diagnosis assessment; the patient tried and had an inadequate response to at least one conservative non-pharmacologic therapy for at least 3 months; the patient tried and had an inadequate response to at least one pharmacologic therapy for at least 3 months; and the patient has not received an intra-articular long-acting corticosteroid agent within the previous 6 months.
    • Treatment course

      • First course: The patient is receiving the first course of any viscosupplement for the requested knee joint.
      • Repeat course: The previous course of viscosupplement for the same knee was at least 6 months prior and the patient had clinical benefit with the requested agent.at least 6 months since prior course
    • Safety and dosing: The patient does not have an FDA-labeled contraindication to the requested agent, and the requested quantity or dose is within FDA-labeled dosing for the requested indication.FDA-labeled dosing

    Patients who received an intra-articular long-acting corticosteroid agent, such as Zilretta, within the previous 6 months are excluded from approval.

    Patients with an FDA-labeled contraindication to the requested agent are excluded from approval.

    Documentation and Authorization Requirements

    Prior Authorization

    All Clinical Criteria Required

    Approval requires all applicable clinical criteria to be met for the requested viscosupplement: qualifying knee osteoarthritis, function-limiting pain not attributable to another joint disease, required conservative-therapy trials with inadequate response, appropriate corticosteroid timing, no FDA-labeled contraindication, eligible initial or repeat-course status, and FDA-labeled dosing.

    Step Therapy

    Conservative Therapy Trials

    Document inadequate response after at least a 3-month trial of both one non-pharmacologic therapy and one pharmacologic therapy.

    • Non-pharmacologic examples: exercise, weight loss, tai chi, knee brace, cane, and self-efficacy/self-management programs.
    • Pharmacologic examples: oral or topical NSAIDs, acetaminophen, duloxetine, topical capsaicin, and tramadol.

    Policy Background

    This policy addresses intra-articular viscosupplementation for osteoarthritis of the knee. Qualifying knee osteoarthritis may be established by at least one specified radiographic finding—joint space narrowing, sub-chondral sclerosis, or osteophytes and sub-chondral cysts—or by at least 5 qualifying clinical or laboratory findings. Treatment is intended for patients with pain that interferes with functional activities, such as walking or prolonged standing, when the pain is not attributed to another joint disease and the patient has had an inadequate response to required conservative non-pharmacologic and pharmacologic therapies, each used for at least 3 months.

    Clinical Definitions

    Crepitus
    DefinitionA noisy, grating sound on active motion.
    Erythrocyte sedimentation rate
    Qualifying thresholdErythrocyte sedimentation rate (ESR) less than 40 mm/hr.
    Qualifying synovial fluid signs
    AppearanceClear synovial fluid.
    ViscosityNormal viscosity.
    White blood cell countLess than 2,000/mm3.

    First Viscosupplementation Course

    First viscosupplementation course

    Initial therapy is approved when the patient is receiving the first course of any viscosupplement for the requested knee joint and all other approval criteria are met.

    Initial therapy: The patient is receiving the first course of any viscosupplement for the requested knee joint.first course

    All other policy approval criteria also apply.

    Repeat Viscosupplementation Course

    Repeat viscosupplementation course

    Repeat therapy is approved when all of the following are met.

    Continuation therapy

    • Prior-course timing and benefit: The patient's previous course of viscosupplement for the same knee joint was at least 6 months prior to this request and the patient had clinical benefit with the requested agent.at least 6 months since prior course
    • Dosing: The requested quantity or dose is within the FDA-labeled dosing for the requested indication.FDA-labeled dosing

    Required Conservative Therapy

    StepRequired therapyMinimum durationRequired response
    1At least one conservative non-pharmacologic therapy, such as exercise, weight loss, tai chi, a knee brace, a cane, or a self-efficacy and self-management programAt least 3 monthsInadequate response
    StepRequired therapyMinimum durationRequired response
    2At least one pharmacologic therapy, such as an oral or topical NSAID, acetaminophen, duloxetine, topical capsaicin, or tramadolAt least 3 monthsInadequate response

    Dosing and Quantity Requirements

    Requested viscosupplementation agent
    Requested quantity or doseMust be within FDA-labeled dosing for the requested indication.
    Policy Summary
    PayerPrime Therapeutics
    PolicyViscosupplementation for Osteoarthritis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date03-15-2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming qualifying knee osteoarthritis, required treatment trials, appropriate treatment timing, absence of contraindications, and FDA-labeled dosing.
    SourceLink
    On This Page
    Viscosupplementation Coverage CriteriaDocumentation and Authorization RequirementsPolicy BackgroundClinical DefinitionsFirst Viscosupplementation CourseRepeat Viscosupplementation CourseRequired Conservative TherapyDosing and Quantity Requirements
    Documentation Required

    Document Diagnosis and Treatment History

    Document knee osteoarthritis and the treatment history supporting medical necessity. The record must show qualifying radiographic or clinical findings, functional pain, exclusion of other joint disease, and prior conservative-therapy trials with inadequate response.

    • Radiographic evidence: one or more of joint-space narrowing; subchondral sclerosis; or osteophytes and subchondral cysts.
    • Alternatively, document at least five clinical findings: bony enlargement; bony tenderness; crepitus with active motion; ESR less than 40 mm/hr; morning stiffness less than 30 minutes; no palpable synovial warmth; rheumatoid factor less than 1:40 titer; or clear, normal-viscosity synovial fluid with WBC less than 2,000/mm³.
    • Document pain interfering with functional activities such as walking or prolonged standing and a differential diagnosis assessment showing the pain is not due to another joint disease, such as rheumatoid or psoriatic arthritis.
    Documentation Required

    Repeat-Course Eligibility and Dosing

    For a repeat course, document that the previous viscosupplement course for the same knee joint was at least 6 months before the request and that the patient experienced clinical benefit with the requested agent. Also document that the requested quantity is within FDA-labeled dosing for the indication.

    • Initial course: the patient is receiving the first course of any viscosupplement for the requested knee joint.
    • Repeat course: prior treatment was at least 6 months earlier and produced clinical benefit.
    Denial Risk

    Clinical Criteria Not Met

    Authorization is not supported when the record does not establish qualifying knee osteoarthritis, function-limiting pain, or the required treatment history. Requests may be denied when the applicable approval criteria are absent or cannot be documented.

    • No qualifying radiographic findings or sufficient clinical findings to establish knee osteoarthritis.
    • Pain does not interfere with functional activity or is attributable to another joint disease.
    • No documented inadequate response to the required non-pharmacologic and pharmacologic therapy trials.
    Denial Risk

    Recent Corticosteroid Therapy or Contraindication

    Deny the request when the patient received an intra-articular long-acting corticosteroid, such as Zilretta, within the previous 6 months, or when the requested agent has an FDA-labeled contraindication for the patient.

    • Verify the date of any intra-articular long-acting corticosteroid therapy.
    • Screen for and document the absence of FDA-labeled contraindications to the requested agent.
    Denial Risk

    Repeat-Course or Dosing Requirements Not Met

    A repeat-course request does not meet criteria when the prior course for the same knee was less than 6 months ago or when clinical benefit from the requested agent is not documented. Deny or revise requests for quantities or dosing outside the FDA label for the requested indication.

    • Insufficient interval between viscosupplement courses: less than 6 months.
    • No documented clinical benefit with the requested agent for the prior course.
    • Requested quantity or dose exceeds or otherwise falls outside FDA-labeled dosing.